Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hang, Wang, Tao, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326472/
https://www.ncbi.nlm.nih.gov/pubmed/25539790
http://dx.doi.org/10.1186/1477-7819-12-393
Descripción
Sumario:BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare. CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family. CONCLUSION: Goserelin plus endocrine treatments may benefit male breast cancer.

Ejemplares similares